Orocidin and Syngene Partner to Accelerate Biotech Innovation
Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced a strategic partnership with Syngene International . The collaboration aims to advance GMP peptide development programs using cutting-edge technology and scalable solutions.
The partnership will focus on developing Orocidin's QR-01, leveraging Syngene's capabilities in efficient and scalable manufacturing with reduced lead times. Syngene's infrastructure will provide access to skilled scientists and state-of-the-art facilities, ensuring a robust and streamlined supply chain for future commercialization.
This strategic alliance aligns with Nordicus Partners' specialization in supporting Nordic and U.S. life sciences companies establishing themselves in the U.S. market.
Orocidin A/S, una filiale di Nordicus Partners (OTCQB: NORD), ha annunciato una partnership strategica con Syngene International. La collaborazione mira a promuovere programmi di sviluppo di peptidi GMP utilizzando tecnologie all'avanguardia e soluzioni scalabili.
La partnership si concentrerà sullo sviluppo del QR-01 di Orocidin, sfruttando le capacità di Syngene nella produzione efficiente e scalabile con tempi di consegna ridotti. L'infrastruttura di Syngene garantirà accesso a scienziati qualificati e strutture all'avanguardia, assicurando una catena di approvvigionamento solida e semplificata per la futura commercializzazione.
Questa alleanza strategica si allinea con la specializzazione di Nordicus Partners nel supportare le aziende nordiche e statunitensi nel loro insediamento nel mercato statunitense.
Orocidin A/S, una subsidiaria de Nordicus Partners (OTCQB: NORD), ha anunciado una asociación estratégica con Syngene International. La colaboración tiene como objetivo avanzar en programas de desarrollo de péptidos GMP utilizando tecnología de vanguardia y soluciones escalables.
La asociación se centrará en el desarrollo del QR-01 de Orocidin, aprovechando las capacidades de Syngene en fabricación eficiente y escalable con tiempos de entrega reducidos. La infraestructura de Syngene proporcionará acceso a científicos altamente capacitados e instalaciones de última generación, asegurando una cadena de suministro robusta y optimizada para la futura comercialización.
Esta alianza estratégica se alinea con la especialización de Nordicus Partners en apoyar a las empresas de ciencias de la vida de los países nórdicos y de EE. UU. en su establecimiento en el mercado estadounidense.
Orocidin A/S는 Nordicus Partners (OTCQB: NORD)의 자회사로서 Syngene International과 전략적 파트너십을 발표했습니다. 이 협력은 최첨단 기술과 확장 가능한 솔루션을 사용하여 GMP 펩타이드 개발 프로그램을 발전시키는 것을 목표로 합니다.
파트너십은 Orocidin의 QR-01 개발에 중점을 두며, Syngene의 효율적이고 확장 가능한 제조 능력을 활용하여 리드 타임을 단축할 것입니다. Syngene의 인프라는 숙련된 과학자와 최첨단 시설에 대한 접근을 제공하여 향후 상용화를 위한 강력하고 효율적인 공급망을 보장합니다.
이 전략적 동맹은 Nordicus Partners의 전문성과 일치하며, 북유럽 및 미국 생명 과학 기업들이 미국 시장에 자리 잡는 것을 지원합니다.
Orocidin A/S, une filiale de Nordicus Partners (OTCQB: NORD), a annoncé un partenariat stratégique avec Syngene International. Cette collaboration vise à faire avancer des programmes de développement de peptides GMP en utilisant des technologies de pointe et des solutions évolutives.
Le partenariat se concentrera sur le développement du QR-01 d'Orocidin, en tirant parti des capacités de Syngene en matière de fabrication efficace et évolutive avec des délais de livraison réduits. L'infrastructure de Syngene fournira un accès à des scientifiques qualifiés et à des installations de pointe, garantissant une chaîne d'approvisionnement robuste et rationalisée pour la future commercialisation.
Cette alliance stratégique s'inscrit dans la spécialisation de Nordicus Partners, qui soutient les entreprises de sciences de la vie des pays nordiques et des États-Unis dans leur établissement sur le marché américain.
Orocidin A/S, eine Tochtergesellschaft von Nordicus Partners (OTCQB: NORD), hat eine strategische Partnerschaft mit Syngene International bekannt gegeben. Die Zusammenarbeit zielt darauf ab, GMP-Peptidentwicklungsprogramme mit modernster Technologie und skalierbaren Lösungen voranzutreiben.
Der Fokus der Partnerschaft liegt auf der Entwicklung von Orocidins QR-01, wobei die Fähigkeiten von Syngene in der effizienten und skalierbaren Herstellung mit verkürzten Lieferzeiten genutzt werden. Die Infrastruktur von Syngene wird den Zugang zu qualifizierten Wissenschaftlern und modernen Einrichtungen ermöglichen und eine robuste und optimierte Lieferkette für die zukünftige Vermarktung gewährleisten.
Diese strategische Allianz entspricht der Spezialisierung von Nordicus Partners, nordische und US-amerikanische Unternehmen im Bereich der Lebenswissenschaften bei der Etablierung auf dem US-Markt zu unterstützen.
- Strategic partnership secured with established peptide development company
- Access gained to advanced manufacturing capabilities and skilled scientists
- Potential for reduced lead times in product development
- Enhanced supply chain optimization for future commercialization
- None.
BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces a strategic partnership with Syngene International Limited (“Syngene”),
Syngene’s mission is to work as an extension of its client’s team. Together the teams solve the complex challenges associated with GMP peptide development programs using cutting-edge technology and scalable solutions, while maintaining the highest quality standards. Syngene’s capabilities enable efficient and scalable manufacturing with reduced lead times, ensuring the most robust and streamlined supply chain for future commercialization.
“We are very impressed with Syngene’s professionalism, commitment to scientific excellence, and ability to deliver high-quality work on time,” said Allan Wehnert, CEO & Founder of Orocidin. “This partnership secures access to highly skilled scientists and state-of-the-art facilities ensuring the development and progress of Orocidin’s QR-01.”
Alex Del Priore, Senior Vice President – Development & Manufacturing Services, Syngene International Ltd added: "We are delighted to partner with Orocidin in advancing their peptide programs. With a shared focus on speed, scale, and supply chain security, Syngene is well positioned to help biotech companies like Oricidin bring new drugs to market faster and more reliably.”
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401
About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Syngene
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.2 Mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company’s latest Environmental, Social, and Governance (ESG) report, visit https://esgreport.syngeneintl.com.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What is the purpose of the Orocidin-Syngene partnership announced by NORD?
How will the Syngene partnership benefit NORD's subsidiary Orocidin?
What specific product is being developed through the NORD-Syngene collaboration?
How does the Syngene partnership align with NORD's business strategy?
